ClinVar Miner

Submissions for variant NM_000335.5(SCN5A):c.5708C>T (p.Ser1903Leu) (rs150264233)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000041630 SCV000065326 likely benign not specified 2020-08-05 criteria provided, single submitter clinical testing The p.Ser1904Leu variant in SCN5A has been reported in several individuals with a range of cardiac manifestations (Bankston 2007 PMID: 18708744, Kapplinger 2010 PMID: 20129283, Methner 2016 PMID: 27435932, LMM data). However, this variant has also been identified in 0.17% (42/24204) of African chromosomes by gnomAD (http://gnomad.broadinstitute.org). This frequency is inconsistent with the reported prevalence of SCN5A-associated disease. This variant has also been reported in ClinVar (Variation ID: 48310). Computational prediction tools and conservation analyses predict an impact to the protein and in vitro studies suggest that the p.Ser1904Leu variant may impact protein function (Bankston 2007 PMID: 18708744, Glaaser 2012 PMID: 22426227, Kapplinger 2010 PMID: 20129283). However, this in vitro assay may not accurately represent biological function. In summary, because of the frequency, this variant is classified as likely benign. ACMG/AMP Criteria applied: PP3, PS4_Supporting, BS1.
GeneDx RCV000058802 SCV000235543 uncertain significance not provided 2021-08-24 criteria provided, single submitter clinical testing Published functional studies demonstrate S1904L disrupts voltage-gated Na(+) channel inactivation (Bankston et al., 2007; Glaaser et al., 2012); nevertheless, it is unclear how these studies may translate to a pathogenic role in vivo; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Reported in ClinVar (ClinVar Variant ID# 48310; Landrum et al., 2016); This variant is associated with the following publications: (PMID: 26582918, 25904541, 30847666, 28988457, 29728395, 18708744, 27435932, 24892747, 26332594, 20129283, 26159999, 22426227, 25637381, 22378279, 24055113)
Invitae RCV001083009 SCV000637187 likely benign Brugada syndrome 2020-11-25 criteria provided, single submitter clinical testing
Ambry Genetics RCV000620507 SCV000737262 likely benign Cardiovascular phenotype 2019-01-18 criteria provided, single submitter clinical testing Other data supporting benign classification;Subpopulation frequency in support of benign classification
Mendelics RCV000987195 SCV001136444 benign Brugada syndrome 1 2019-05-28 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000041630 SCV001338525 likely benign not specified 2020-04-13 criteria provided, single submitter clinical testing Variant summary: SCN5A c.5711C>T (p.Ser1904Leu) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00017 in 283812 control chromosomes, predominantly at a frequency of 0.0017 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 68- fold the estimated maximal expected allele frequency for a pathogenic variant in SCN5A causing Cardiomyopathy phenotype (2.5e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. c.5711C>T has been reported in at least one individual with LQTS and segregated with symptoms of disease in two family members, however only a subset of LQTS-associated genes were sequenced in these individuals (Bankston_2007). In addition, the variant has been reported in at least one individual affected with SIDS (Methner_2017). These reports do not provide unequivocal conclusions about association of the variant with Cardiomyopathy. Several publications report experimental evidence evaluating an impact on protein function. These studies report that the variant disrupts sodium channel gate inactivation and promotes late Na+ channel currents by increasing the propensity of the channel to reopen during prolonged depolarization (Bankston_2007, Glaaser_2012). In addition, one study reports that the variant may have a more severe electrophysiological impact in certain tissue types, as the effect in Purkinje fiber cells was more significant than that observed in a ventricular myocyte model (Iyer_2014). These in-vitro studies do not allow convincing conclusions about the variant effect, however, as the variant does not appear to alter the overall function of the sodium channels and it is unclear how these findings would translate in-vivo. Six ClinVar submitters (evaluation after 2014) cite the variant with conflicting interpretations: benign (n=1), likely benign (n=2), uncertain significance (n=2), and pathogenic (n=1). Based on the evidence outlined above, the variant was classified as likely benign.
Color Health, Inc RCV001192115 SCV001360092 likely benign Arrhythmia 2018-11-24 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV000058802 SCV001713278 uncertain significance not provided 2019-06-23 criteria provided, single submitter clinical testing
Cardiovascular Biomedical Research Unit,Royal Brompton & Harefield NHS Foundation Trust RCV000058802 SCV000090322 not provided not provided no assertion provided literature only This variant has been reported in the following publications (PMID:18708744;PMID:20129283;PMID:22378279;PMID:22426227).
CSER _CC_NCGL, University of Washington RCV000148839 SCV000190580 likely benign Long QT syndrome 2014-06-01 no assertion criteria provided research
Forensic Genetics Laboratory,Harris County Institute of Forensic Sciences RCV000234983 SCV000263116 pathogenic Death in infancy 2015-03-27 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.